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Background: Sickle cell anaemia (SCA) is prevalent in sub-Saharan Africa, with high risk of complications requiring
emergency care. There is limited information about presentation of patients with SCA to hospitals for emergency
care. We describe the clinical presentation, resource utilization, and outcomes of SCA patients presenting to the
emergency department (ED) at Muhimbili National Hospital (MNH) in Dar es Salaam, Tanzania.
Methods: This was a prospective cohort study of consecutive patients with SCA presenting to ED between December
2014 and July 2015. Informed consent was obtained from all patients or patients’ proxies prior to being enrolled in the
study. A standardized case report form was used to record study information, including demographics, relevant clinical
characteristics and overall patients outcomes. Categorical variables were compared with chi-square test or Fisher’s
exact test; continuous variables were compared with two-sample t-test or Mann-Whitney U-test.
Results: We enrolled 752 (2.7%) people with SCA from 28,322 patients who presented to the MNH-ED. The median
age was 14 years (Interquartile range [IQR]: 6–23 years), and 395 (52.8%) were female. Pain 614 (81.6%), fever 289 (38.
4%) were the most frequent presenting complaint. Patients with fever, hypoxia, altered mental status and bradycardia
had statistically significant relative risk of mortality of 10.4, 153, 50 and 12.1 (p < 0.0001) respectively, compared to
patients with normal vitals. Overall, 656 (87.2%) patients received Complete Blood Cell counts test, of these 342 (52.1%)
had severe anaemia (haemoglobin < 7 g/dl), and a 30.3 (p = 0.02) relative risk of relative risk of mortality compare to
patients with higher haemoglobin. Patients who had malaria, elevated renal function test and hypoglycemia, had
relative risk of mortality of 22.9, 10.4 and 45.2 (p < 0.0001) respectively, compared to patient with normal values. Most
534 (71.0%) patients were hospitalized for in patients care, and the overall morality rate was 16 (2.1%).
Conclusions: We described the clinical presentation, management, and outcomes of patients with SCA presenting to
the largest public ED in Tanzania, as well as information on resource utilization. This information can inform
development of treatment guidelines, clinical staff education, and clinical research aimed at optimizing care for SCA
patients.
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Sickle cell disease (SCD) is one of the most common
genetic diseases in the world, with the highest preva-
lence in sub-Saharan Africa, the Caribbean, the Mid-
dle East and India [1]. The morbidity and mortality
from Sickle Cell Anaemia (SCA) in developed coun-
tries has improved significantly over the last five
decades, with studies showing median survival rates
beyond the fifth decade of life [2]. In developing
countries, however, SCA still causes significant mor-
bidity and mortality with the greatest burden of the
disease in sub-Saharan Africa. The World Health
Organization (WHO) estimates over half of children
born with SCA in sub-Saharan Africa will die before
they reach adulthood [3]. Infectious diseases, such as
malaria and pneumococcal disease (meningitis, pneu-
monia, and septicaemia) are thought to be the major
cause of morbidity and mortality [4, 5].
Tanzania ranks fifth in the world for number of SCD
births with an estimated prevalence of 6 [interquartile
range (IQR) 1–13] per 1000 births, equivalent to 11,000
SCD births per year [4, 6]. A study conducted at a uni-
versity teaching hospital in Tanzania reported a SCA
mortality rate of 1.9 per 100 person years of observation
(PYO), with the highest incidence of death occurring in
the first five years of life [7]. Overall median survival in
this study was 33 years. Of note, life expectancy of Tan-
zanian residents is 52 years. Similar to other developing
countries, morbidity and mortality due to SCA in
Tanzania is highly influenced by comorbid conditions,
such as infections (particularly malaria), anaemia, and
poor nutrition [4].
Emergency department (ED) presentations of SCA
complications are well characterized in developed
countries, with the majority of these patients present-
ing with pain crisis [8–12]. Most of these patients are
treated with aggressive pain management and fluid
therapy and discharged home, with less than
one-third admitted to the hospital. In 2010, Muhim-
bili National Hospital (MNH), which is the main Uni-
versity Teaching Hospital, opened the first full
capacity, high-volume ED in Tanzania. This ED has
provided an opportunity for early stabilization and re-
suscitation of acutely ill patients, including those with
SCA. The study on mortality in SCA in Africa pub-
lished in 2011 was conducted at the same hospital, at
that time had no full capacity ED [7]. This is critical
as little is known about the acute or emergent mani-
festations, management, and outcomes of SCA com-
plications in Tanzania. The primary aim of this
investigation is to describe the clinical presentation,
ED management, and hospital outcomes of individuals
known or suspected to have sickle cell disease and
presenting to the MNH ED.Methods
Study design and setting
This was a prospective observational study of consecu-
tive patients presenting to the MNH ED in Dar es
Salaam, Tanzania, from 1 December 2014 to 31 July
2015. MNH has a bed capacity of 1500 and serves as the
top referral hospital in Tanzania. The ED was established
in 2010 via a partnership between the Ministry of Health
and Social Welfare, and Abbott Fund Tanzania. The ED
is the first full capacity public ED in Tanzania, and the
training site for the only emergency medicine (EM) resi-
dency program in the country. The department is staffed
24 h, seven days a week by locally trained specialist
emergency physicians, who oversee the care of patients
and training of interns, registrars, and EM residents.
The ED sees an average of 45,000 patients annually, with
an admission rate of around 65%. The top disease
categories in all age groups are trauma, infectious dis-
ease, and mental health [13]. MNH is one of the largest
SCD treatment and research centre in Tanzania. The
diagnosis of SCA at MNH is normally confirmed by the
haemoglobin electrophoresis, after initial sickling test or
clinical suspicion at most of the referring hospitals.
Patients confirmed to have SCA are enrolled into a
Sickle Cell clinic, provided with dedicated medical rec-
ord number and special follow up card. In this study, all
patients with confirmed evidence of SCA presenting
with acute illness at the ED were eligible for enrolment.
Study protocol
Screening and enrolment was completed by a research
assistant and the study investigator (HS). A structured
data sheet was used to record study information, includ-
ing demographics, pre-referral information, chief
complaints, initial vital signs, history and physical exam-
ination findings, laboratory results, treatment delivered,
and final ED diagnoses and disposition. All diagnostic,
treatment, and disposition decisions were made at the
discretion of the treating physician. The research assist-
ant followed up on all enrolled patients throughout the
duration of their hospital study and recorded lengths of
stay in hospital and intensive care unit (ICU) or high
acuity ward, as well as final hospital diagnosis and
clinical outcome (discharge or death) for each patient.
Data analysis
Information collected from the handwritten data sheets
were transferred into an Excel spreadsheet (Microsoft
Corporation, Redmond, WA, USA), verified, and checked
for any errors and outliers. Data were subsequently
imported into StatsDirect (version 3.0.167, StatsDirect
Ltd., Cheshire, UK) for analysis. Categorical variables were
summarized as frequencies and percentages, and continu-
ous variables as means and standard deviations (SD) or
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data distribution. Normality was assessed using the
Shapiro-Wilk test. Ninety-five percent confidence inter-
vals (CI) are presented where appropriate, and were calcu-
lated by the Clopper-Pearson (exact) method. Categorical
variables were compared with chi-square test or Fisher’s
exact test; continuous variables were compared with
two-sample t-test or Mann-Whitney U-test. Two-tailed
p-values of < 0.05 were considered statistically significant.
Results
We enrolled 752 (2.7%) people with SCA from 28,322
patients who presented to the MNH ED from 1 Decem-
ber 2014 to 31 July 2015. The median age of enrolled pa-
tients was 14 years (Interquartile range (IQR) of 6–
23 years), with 19.7% younger than age 5, and 52.9%
were female. A total of 299 (40.2%) patients were re-
ferred from peripheral hospitals, the median length of
admission at these peripheral facilities prior to referral
was 2 days (IQR 1.3 days) Table 1.
Patients’ baseline variables and presenting complaints
Tachypnea 336 (44.7%) was the most frequent abnormal
vital sign among enrolled patients, while bradycardia 14
(1.9%) was the least frequent abnormal sign. All the
abnormality are based on age-appropriate vital signs
[14]. Patients who presented fever 289 (17.4%), hypoxia
67 (8.9%), altered mental status 59 (7.8%) and bradycar-
dia 14 (1.9%) had a statistically significant higher relative
risk of death compared with those without bradycar-
dia. Pain 614 (81.6%) and urinary symptoms 6 (0.8%)
were most and least frequent presenting complaints
respectively Table 2.
Investigations ordered in the ED
Nearly all patients 744 (99%) had at least one laboratory
test done while receiving ED care. Complete blood cell
counts were ordered for 656 (87.2%) patients. Of these
346 (52.7%) had elevated white blood counts (> 11 K/uL)Table 1 Patient demographics
Demographics Number Percentage (%)
Sex N = 747
Female 395 52.9
Male 352 47.1
Age Group N = 741
1 month–< 5 years 146 19.7
5 years–< 18 years 304 41.0
≥ 18 years 291 39.3
Referral Status N = 744
Self referral 445 59.8
Referred 299 40.2and 342 (52.1%) had severe anaemia (Hb < 7 g/dL) of
which 166 (25.3%) had (Hb < 5 g/dL). Of the 415 patients
tested for malaria, 48 (11.6%) were positive. The relative
risk of death among those with severe anaemia, malaria
test positive, elevated renal function test and
hypoglycaemia was 30.3, 22.9,10.4 and 45.2 respectively.
X-ray of the chest was ordered in 85 (11.3%) of patients,
and the relative risk of death among those with an
abnormal chest x-ray was 4.0 (Table 3).
Final ED diagnosis
The top three ED diagnoses were painful crisis (n = 472;
62.8%), malaria (n = 176; 23.4%), and severe anaemia (n
= 117; 15.6%) (Table 4).
ED treatment and interventions
In the ED, intravenous fluid bolus and intravenous dex-
trose were given to 370 (49.2%) and 129 (17.2%) of en-
rolled patients, respectively. A total of 489 patients
(65.0%) received analgesics for pain, with 350 (71.6%)
receiving opioid analgesics. Antimalarial were adminis-
tered in the ED to 123 (16.4%) patients, while 220
(29.3%) received antibiotics, the majority of whom
(89.2%) received intravenous ceftriaxone. Seventy-two
patients (9.6%) received blood products (fresh whole
blood, packed red cells, or fresh frozen plasma), with the
majority (91.2%) receiving fresh whole blood.
Patients’ disposition and hospital outcomes
Of the 752 SCA patients seen in the ED, 534 (71%) were
hospitalized for inpatient care, while five patients (0.7%)
died in the ED. The median length of stay in hospital
was 3 days (Interquartile range (IQR): 1–5) days. The
overall morality (ED plus inpatient) was 16 (2.1%). Over-
all, 8 (50%) of deaths’ occurred within 24 h of ED pres-
entation (Table 5).
Discussion
The opening of a full capacity ED at MNH provided a
unique opportunity for rapid assessment and early
stabilization of acutely ill individuals, including those
with SCA. Our study reports on the clinical profile and
management of acutely ill individuals with SCA present-
ing to an urban ED in Tanzania. This information on ED
access and resource utilization can be useful in develop-
ing local and countrywide strategies to improve access,
treatment guidelines, and health outcomes among indi-
viduals with SCA.
In our study, the prevalence of SCA among acutely ill
patients presenting ED was found to be 2.7%, and most
of the patients were self-referral, highlighting the role of
ED as a major mode of healthcare utilization in this
patient population in Tanzania. Most of our patients
were children below eighteen years, an observation
Table 2 Patients’ baseline variables and presenting complaints
Overall Died Survived Relative risk P-value
N = 752 N = 16 N = 736
Clinical characteristics n (%) n (%) n (%) RR (95%CI)
Tachypnea b 336 (44.7) 10 (62.5) 326 (44.3) 2.1 (0.8–5.7) 0.16
Tachycardiab 186 (24.7) 5 (31.3) 181 (24.6) 1.4 (0.5–3.9) 0.5
Febrile (T > 37.5 °C)c 131 (17.4) 11 (68.8) 120 (16.3) 10.4 (3.7–29.5) < 0.0001
SpO2
a < 95% 67 (8.9) 15 (93.8) 52 (7.1) 153 (20–1143) < 0.0001
Altered mental status 59 (7.8) 13 (81.3) 46 (6.3) 50 (15–174) < 0.0001
Bradycardiab 14 (1.9) 3 (18.8) 11 (1.5) 12.1 (3.9–38.0) < 0.0001
Pain 614 (81.6) 12 (75.0) 602 (81.8) 0.7 (0.2–2.1) 0.5
Fever 289 (38.4) 10 (62.5) 279 (37.9) 2.7 (1.0–7.3) 0.06
Abdominal Symptoms 159 (21.1) 2 (12.5) 157 (21.3) 0.5 (0.1–2.3) 0.4
Respiratory Symptoms 156 (20.7) 11 (68.8) 145 (19.7) 8.4 (3.0–23.8) 0.0001
Cardiovascular Symptoms 83 (11.0) 2 (12.5) 81 (11.0) 1.2 (0.3–5.0) 0.9
Jaundice 80 (10.6) 1 (6.3) 79 (10.7) 0.6 (0.1–4.2) 0.6
Body Swelling 54 (7.2) 2 (12.5) 52 (7.1) 1.9 (0.4–7.9) 0.4
Neurological Symptoms 45 (6.0) 6 (37.5) 39 (5.3) 9.4 (3.6–24.8) < 0.0001
Long Lasting Erection 20 (2.7) 1 (6.3) 19 (2.6) 2.4 (0.3–17.6) 0.4
Urinary Symptoms 6 (0.8) 1 (6.3) 5 (0.7) 8.3 (1.3–53.1) 0.03
aSpO2 Saturation of oxygen in peripheral capillary
bAge-adjusted variables c Measurements were all axillary
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same settings [7].
Pain was the most common presenting complaints
among patients presenting to ED. Vaso-occlusive painful
crisis phenomena is a well documented reason for ED
visit among sickle cell patients in different settings [7, 8],
and it has been shown to be a potential marker of ser-
ious illness, which may be associated with increasedTable 3 Investigations ordered in the ED
Overall Died
n/N (%) n/N (%)
Laboratory Tests
WBC Ω (> 11 K/uL) 346/656 (52.7) 11/16 (68.8)
Haemoglobin (< 7 g/dL) 342/656 (52.1) 16/16 (100)
Abnormal urine results δ 11/63 (17.5) 1/16 (6.3)
Malaria test positive 48/415 (11.6) 12/16 (75)
Elevated RFTβ 24/219 (11.0) 9/16 (56.3)
Low RBGη (< 3 mmol/L) 39/627 (6.2) 12/16 (75)
Imaging Tests
Abnormal chest x-ray α 30/85 (35.3) 11/16 (68.8)
Abnormal brain CT scan ρ 7/26 (26.9) 5/16 (31.3)
Ω WBC-White Blood Cell
δ Presence of blood in urine, leukocytes, nitrites, albumin, or glucose
α Signs of infection or stroke
β RFT-Renal function test
η RBG-Random Blood Glucose
α Pneumonic changes
ρ Signs of strokemorbidity and mortality [7, 15]. Respiratory compromise,
denoted by tachypnea and hypoxia (oxygen saturation <
95%), was the most common physical examination find-
ing at presentation. In this population, the most com-
mon reason for respiratory compromise was chest
infection (pneumonia), followed by acute chest syn-
drome. Infection is the leading cause of preventable
morbidity and mortality in patients with SCA, andSurvived Relative risk P-value
n/N (%) RR (95%CI)
335/640 (52.3) 2.0 (0.7–5.6) 0.2
326/640 (50.9) 30.3 (1.8–503) 0.02
10/47 (21.3) 0.3 (0.04–2.11) 0.2
36/399 (9.0) 22.9 (7.7–68) < 0.0001
15/203 (7.4) 10.4 (4.2–25.5) < 0.0001
27/611 (4.4) 45.2 (15.3–133.8) < 0.0001
19/69 (27.5) 4.0 (1.5–10.5) 0.004
2/10 (20) 1.2 (0.67–2.2) 0.5
Table 4 Final ED diagnosis
Final ED Diagnosis N = 752 % (95% CI)
Painful crisis 472 62.8 (59.3–66.2)
Malaria 176 23.4 (20.5–26.6)
Severe anaemia 117 15.6 (13.2–18.3)
Pneumonia 105 14.0 (11.7–16.6)
Acute chest syndrome 49 6.5 (5.0–8.5)
Hypoglycaemia 42 5.6 (4.2–7.5)
Urinary tract infection 41 5.5 (4.0–7.3)
Acute kidney injury 27 3.6 (2.5–5.2)
Priapism 18 2.4 (1.5–3.8)
Cerebral vascular accident 16 2.1 (1.3–3.4)
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USA, in absence of aggressive treatment [16, 17]. Stan-
dardized treatment and prevention (i.e. prophylactic
penicillin and vaccination against pneumococcal infec-
tions) have significantly improved the outcome and
quality of life [18]; however, these interventions are not
routinely available to our patient population as they are
not part of standard care [19]. When present, bradycar-
dia, altered mental status, and hypoxia were each associ-
ated with a relative risk of death of greater than 10 in
our study population compared to when these features
were absent.
In addition to physical examinations, most of these pa-
tients received laboratory and imaging tests. More than
three-quarters of patients had a complete blood cell
count as part of their ED care, more than half of who
had severe anaemia. All patients who died had severe
anaemia at presentation. Severe anaemia was associated
with a significantly higher relative risk of death when
compared with higher haemoglobin levels. These find-
ings are similar to previous literature in similar settings,
which have shown low haemoglobin to be anTable 5 Patients’ disposition and hospital outcomes
Disposition N = 752 % (95% CI)
Admitted 534 71.0 (67.6–74.2)
Discharged from ED 213 28.3 (25.1–31.7)
Died in ED 5 0.7 (0.3–1.5)
Death within 24-h of ED presentation ϖ 8 1.1 (0.5–2.1)
Inpatient mortality φ 11 2.1 (1.2–3.7)
Overall mortality 16 2.1 (1.3–3.4)
Median IQR
Median length of hospital stay 3 days 1–5 days
ϖ Includes ED and inpatient deaths
φ Includes only in patients’ deaths (denominator: N = 534) those who
were admittedindependent predictor of mortality in patients with SCA
[16, 20]. Severe anaemia is reported to negatively impact
outcome and quality of life in SCA patients [20]. In our
patient cohort, only 21% of patients with severe anaemia
received blood transfusion in the ED. The current local
guideline for management of severe anaemia in patients
with SCA recommends blood transfusion to all SCA pa-
tients with haemoglobin (Hb) less than 5 g/dL, regard-
less of presenting complaint, and to those with Hb <
7 g/dL if symptomatic [21]. In this study population,
25.3% of patients had haemoglobin less than 5 g/dL, but
overall more than half of patients who should receive
blood products as part of their ED care did not receive
it. Several factors may impact availability, access, and
transfusion practices in our ED, including lack of enough
eligible donors, lack of testing and storage equipment,
lack of recognition and late presentation [22, 23]. We
are unable to determine the exact reasons for the low
rate of transfusion in our study. Thus, we recommend
further study to address what appears to be a significant
opportunity for improvement in emergency care of acute
SCA cases. The findings of hypoglycaemia, positive mal-
aria test, abnormal renal function tests and abnormal
chest x-ray findings were all associated with a signifi-
cantly higher relative risk of death compared to patients
with normal results. All of these abnormal findings are
easily manageable at MNH, and at most of the basic fa-
cilities within Tanzania, hence further studies should
focus on addressing the challenges associated with care
and factors associated with mortality within these condi-
tions so as to ensure death from these conditions are
prevented.
Painful crisis, malaria and severe anaemia were the top
three ED providers’ diagnosis. Malaria was diagnosed in
176 patients by ED providers, while only 48 of patients
tested positive, this might indicate an over diagnosis
by ED providers, however we were unable to detect
whether the providers used syndrome approach to
treatment of malaria which calls for use of antimalar-
ial for suspicious cases regardless of the malaria test
results [24].
Over two-thirds of patients were admitted for in-
patient care after initial stabilization in the ED. This is a
much higher admission rate than reported in many de-
veloped countries [8, 10, 12], but similar to the overall
ED disposition patterns in our setting [13]. The overall
mortality in our study population was 2.1%, with 50% of
the deaths occurring within the first 24 h of presentation
to the ED. Our results show that severe anaemia, infec-
tion (malaria and bacterial infection), and hypoxia are
associated with increase in mortality in our study popu-
lation. These contributors should receive focused atten-
tion in the design of ED care protocols for SCA and
further studies.
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The generalizability of our results may be limited due to
the single-centre nature of our study. The ED at MNH
is the entry point to the largest tertiary referral hospital
in Tanzania, and receives acutely ill patients from all
over the country. Therefore, the sample seen at the
MNH ED might be different than that seen at the
district hospitals and health centres. The exclusion of
undiagnosed SCD in our study might have under-estimated
the overall proportion of SCD in our study population. In
addition, the assessment of factors associated with mortality
was limited by the number of deaths in our study
population.
Conclusions
We have provided a description of the clinical presenta-
tion, management, and outcomes of patients with SCA
presenting to the largest public emergency department in
a tertiary referral hospital in Tanzania. These data will in-
form development of strategies to provide education for
clinical staff, treatment guidelines, and clinical research
aimed at optimizing care of the SCA patient population.
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